Price
$8.51-10.61%Social Signal Score
Analyst Ratings
31 analystsRevenue
$167.95M-3.04%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brady Murphy
- Sector
- Energy
- Industry
- Oil & Gas Equipment & Services
- Employees
- 1,400
- Beta
- 1.26
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 2.38
Financials
Revenue
$167.95M-3.0%Net Income
$6.85MEBITDA
$18.61M+132.2%Free Cash Flow
$-26.55M-217.0%EPS (diluted)
$0.05Shares Outstanding (diluted)
149.35M+55.6%Operating Expenses
$25.37MCash & Debt
$126.04MReturn of Capital
$0.00Revenue by Segment (annual)
$630.93MDividend per Share
$0.10Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $630.93M | $3.00M | $0.02 |
| 2024 | $599.11M | $108.28M | $0.82 |
| 2023 | $626.26M | $25.78M | $0.20 |
| 2022 | $553.21M | $7.84M | $0.06 |
| 2021 | $388.27M | $-16.80M | $-0.13 |
| 2020 | $377.71M | $-51.14M | $-0.41 |
| 2019 | $561.24M | $-139.91M | $-1.11 |
| 2018 | $998.77M | $-27.55M | $-0.22 |
| 2017 | $723.10M | $-39.05M | $-0.34 |
| 2016 | $694.76M | $-161.46M | $-1.85 |
| 2015 | $1.13B | $-126.18M | $-1.59 |
| 2014 | $1.08B | $-169.68M | $-2.16 |
| 2013 | $909.40M | $153.0K | $0.00 |
| 2012 | $880.83M | $15.96M | $0.21 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from TTI's reported EPS growth of -15.8% a year over 13 years. Historical EPS growth of -16% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.01
- Implied price
- $0.18
- Return from $5.79
- -50.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.09 — -98.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -25.0% | -59.4% | -57.5% | -55.9% | -54.5% | -53.3% |
| -20.0% | -56.6% | -54.7% | -53.0% | -51.5% | -50.2% |
| -15.0% | -53.9% | -51.8% | -50.0% | -48.5% | -47.1% |
| -10.0% | -51.2% | -49.0% | -47.1% | -45.4% | -44.0% |
| -5.0% | -48.5% | -46.2% | -44.2% | -42.4% | -40.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (12)
- Newsmarketbeat.com·18d ago·Neutral
What Tetra Technologies (TTI) Said on Its Q3 Earnings Call Tetra Technologies NYSE: TTI reported third-quarter 2026 revenue of $168 million, up 10% from a year earlier and the company's highest third-quarter revenue level in a decade, as international activity, industrial chemicals and production testing growth offset lower deepwater completion activity in the Gulf of America.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
TETRA Technologies, Inc. (TTI) Q3 2026 Earnings Call Transcript TETRA Technologies, Inc. ( TTI ) Q3 2026 Earnings Call November 3, 2026 10:00 AM EST Company Participants Kurt Hallead - Treasurer & VP of Investor Relations Brady Murphy - President, CEO & Director Matthew Sanderson - Executive VP & CFO Conference Call Participants Martin Malloy - Johnson Rice & Company, L.L.C., Research Division Patrick Ouellette - Stifel, Nicolaus & Company, Incorporated, Research Division Robert Brooks - Northla…
View source ↗ - Newszacks.com·20d ago·Positive
Tetra Technologies (TTI) Q3 Earnings and Revenues Beat Estimates Tetra Technologies (TTI) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.04 per share a year ago.
View source ↗ - Newsprnewswire.com·20d ago·Positive
…QUARTER 2026 RESULTS Highest Third Quarter Revenue in a Decade SPRING, Texas, Nov. 2, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) announced financial results for the three and nine months ended September 30, 2026. Third-Quarter 2026 Financial Highlights Revenues of $168.0 million, highest third quarter in ten years Net Income of $6.8 million, inclusive of $2.0 million of unusual charges Adjusted EBITDA of $25.1 million Net income per share of $0.05, adjus…
View source ↗ - Newsnewsfilecorp.com·31d ago·Neutral
…unces FDA Clearance of IND for Nephropathic Cystinosis Investigator-initiated study led by Dr. Larry Greenbaum of Emory University to evaluate once-daily oral powder TTI-0102, designed to improve adherence San Diego, California--(Newsfile Corp. - October 22, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application for TTI-0102 …
View source ↗ - Newsprnewswire.com·53d ago·Neutral
TETRA TECHNOLOGIES, INC. ANNOUNCES DATE FOR THIRD QUARTER 2026 EARNINGS CONFERENCE CALL SPRING, Texas, Sept. 30, 2026 /PRNewswire/ -- TETRA Technologies, Inc. (NYSE: TTI) will release Third Quarter 2026 results after the market closes on November 2, 2026 and will host a conference call to discuss the results and outlook on November 3, 2026, at 10:00am ET.
View source ↗ - Newsnewsfilecorp.com·62d ago·Neutral
…d Special Meeting of Shareholders and Provides Corporate Update San Diego, California--(Newsfile Corp. - September 21, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual and Special Meeting of Shareholders ("Meeting") held on September 8, 2026, and provided a corporate update highlighting recent…
View source ↗ - Newsnewsfilecorp.com·80d ago·Neutral
Thiogenesis Engages Brisco Capital for Investor Relations San Diego, California--(Newsfile Corp. - September 3, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing sulfur-based therapeutics for rare diseases, today announced that it has engaged Brisco Capital Partners Corp. ("Brisco") to provide investor relations services. Brisco will assist the Company in expanding communications with shareholder…
View source ↗ - Newsprnewswire.com·81d ago·Neutral
…OLOGIES, INC. TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES SPRING, Texas, Sept. 2, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) announced that Brady Murphy, Chief Executive Officer, and Kurt Hallead, Treasurer and VP of Investor Relations, will be meeting with institutional investors at the following conferences: September 9, 2026: Barclays 40th Annual Energy-Power Conference (NY, NY) September 10, 2026: Jefferies Renewables, Clean Energy and E&C Confer…
View source ↗ - Newsseekingalpha.com·95d ago·Positive
Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript
View source ↗ - Newsmarketbeat.com·105d ago·Neutral
Tetra Technologies Q2 Earnings Call Highlights Tetra Technologies NYSE: TTI reported second-quarter revenue of $185.7 million, up 19% sequentially and 7% from the prior-year period, as strength in international and offshore operations offset delayed Middle East fluid shipments tied to regional conflict.
View source ↗ - Newszacks.com·107d ago·Neutral
Tetra Technologies (TTI) Reports Q2 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Tetra Technologies (TTI) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $0.05 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 2$0.06 vs $0.05beat
- Mon, Aug 3$0.08 vs $0.08beat
- Wed, Apr 29$0.06 vs $0.03beat
- Wed, Feb 25$0.02 vs $0.03miss
- Tue, Oct 28$0.04 vs $0.04beat
- Tue, Jul 29$0.09 vs $0.09beat
Estimates and results for TTI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TTI officers and directors.
- Bought
- $282k
- Sold
- $537k
2 trades
2 trades
- John Angela Dbought
- Murphy Brady Msold
- Murphy Brady Msold
- Hallead Kurtbought
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TTI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
